Larimar Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Nomlabofusp demonstrated sustained increases in frataxin and improvements in key clinical outcomes for Friedreich's ataxia, with a favorable safety profile and strong patient interest. Rolling BLA submission is underway, and a global phase III trial will begin soon, targeting a broad patient population.
-
A novel protein replacement therapy for Friedreich's ataxia shows promising efficacy and safety, with strong biomarker correlations and regulatory momentum. FDA engagement has been collaborative, with a BLA submission planned for June and financial runway secured into 2027.
-
Breakthrough Therapy designation was achieved, with regulatory alignment on frataxin as a surrogate endpoint and a global Phase III trial set to begin U.S. enrollment in Q2. The focus is on pediatric patients, with a flexible market strategy and promising efficacy data compared to competitors.
-
A novel therapy for Friedreich's ataxia shows promise in raising frataxin levels above the critical threshold, improving clinical outcomes and potentially modifying disease progression. Accelerated approval is being pursued, with a phase III trial and regulatory updates underway.
Fiscal Year 2025
-
Nomlabofusp demonstrated robust increases in frataxin and consistent improvements in key clinical outcomes for Friedreich's ataxia, including mFARS, ADL, fine motor coordination, and fatigue, with a favorable safety profile aside from manageable allergic reactions. Accelerated approval is targeted for 2026.
-
FDA provided written guidance for BLA submission, requiring safety data from 30 participants (10 for one year) on the 50 mg dose, shifting the submission to Q2 2026 and targeting a U.S. launch in early 2027. Nomlabofusp continues to show promising safety and efficacy data, with global phase III and open-label studies expanding to broader populations.
-
Development is advancing with all patients now on the 50 mg dose and adolescent studies underway. Regulatory discussions support accelerated approval using frataxin as a surrogate endpoint, with a confirmatory study and BLA filing planned for later this year. Cash reserves support operations into 2026.
Fiscal Year 2024
-
Long-term open-label data show nomlabofusp increases frataxin levels and is generally well tolerated in adults with Friedreich’s Ataxia, with early trends toward clinical improvement, especially in upper limb function. Dose escalation to 50mg and pediatric studies are underway, with pivotal data and BLA submission targeted for 2025.